Insider Transactions in Q3 2023 at Aclaris Therapeutics, Inc. (ACRS)
Insider Transaction List (Q3 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 06
2023
|
Kevin Balthaser Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
9,490
+38.03%
|
$66,430
$7.9 P/Share
|
|
Sep 01
2023
|
Kevin Balthaser Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
285
-4.56%
|
$1,995
$7.9 P/Share
|
|
Sep 01
2023
|
Kevin Balthaser Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+13.78%
|
-
|
|
Aug 28
2023
|
James Loerop Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
14,705
+40.41%
|
$88,230
$6.8 P/Share
|
|
Aug 21
2023
|
Joseph Monahan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,000
-4.23%
|
$42,000
$7.32 P/Share
|
|
Aug 01
2023
|
Douglas J. Manion Pres and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,437
-15.64%
|
$39,933
$9.81 P/Share
|
|
Aug 01
2023
|
Douglas J. Manion Pres and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,575
+35.44%
|
-
|
|
Jul 01
2023
|
Gail Cawkwell Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,407
-36.05%
|
$54,070
$10.37 P/Share
|
|
Jul 01
2023
|
Gail Cawkwell Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
-
|